BRIEF-Adagio Medical To List On Nasdaq Through Business Combination With ARYA Sciences Acquisition Corp IV

Reuters

Feb 14, 2024

Feb 14 (Reuters) - ARYA Sciences Acquisition Corp IV

:

* ADAGIO MEDICAL TO LIST ON NASDAQ THROUGH BUSINESS COMBINATION WITH ARYA SCIENCES ACQUISITION CORP IV, ENABLING FURTHER COMMERCIAL AND CLINICAL DEVELOPMENT OF INNOVATIVE CARDIAC ABLATION TECHNOLOGIES

* ARYA SCIENCES ACQUISITION CORP IV - TRANSACTION IMPLIES A POST-TRANSACTION FULLY DILUTED EQUITY VALUE OF COMBINED COMPANY OF $128 MILLION

* ARYA SCIENCES ACQUISITION CORP IV: COMBINED CO EXPECTS TO RECEIVE ABOUT $42 MILLION FROM EQUITY AND CONVERTIBLE NOTE INVESTORS AT CLOSING

* ARYA SCIENCES ACQUISITION CORP IV - TRANSACTION IMPLIES A POST-TRANSACTION FULLY DILUTED ENTERPRISE VALUE OF $113 MILLION OF COMBINED CO

* ARYA SCIENCES ACQUISITION CORP IV: INC." COMBINED CO'S COMMON STOCK EXPECTED TO BE LISTED ON NASDAQ UNDER TICKER SYMBOL "ADGM"

* ARYA SCIENCES ACQUISITION CORP IV - CURRENT INVESTORS IN ADAGIO MEDICAL ARE EXPECTED TO OWN ABOUT 10.2% OF COMBINED CO

* ARYA SCIENCES ACQUISITION CORP IV - PERCEPTIVE AND ARYA SCIENCES HOLDINGS IV COLLECTIVELY, ARE EXPECTED TO HOLD ABOUT 58.2% OF COMBINED CO

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2411437262"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2411437262\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2411437262?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-02-14 19:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2411437262","market":"us","top_or_hot":-1,"title":"BRIEF-Adagio Medical To List On Nasdaq Through Business Combination With ARYA Sciences Acquisition Corp IV","media":"Reuters","content":"<html><body><p>Feb 14 (Reuters) - <a href=\"https://laohu8.com/S/ARYD\">ARYA Sciences Acquisition Corp IV</a></p><p> :</p><p>   * ADAGIO MEDICAL TO LIST ON NASDAQ THROUGH BUSINESS COMBINATION WITH ARYA SCIENCES ACQUISITION CORP IV, ENABLING FURTHER COMMERCIAL AND CLINICAL DEVELOPMENT OF INNOVATIVE CARDIAC ABLATION TECHNOLOGIES</p><p>   * ARYA SCIENCES ACQUISITION CORP IV - TRANSACTION IMPLIES A POST-TRANSACTION FULLY DILUTED EQUITY VALUE OF COMBINED COMPANY OF $128 MILLION</p><p>   * ARYA SCIENCES ACQUISITION CORP IV: COMBINED CO EXPECTS TO RECEIVE ABOUT $42 MILLION FROM EQUITY AND CONVERTIBLE NOTE INVESTORS AT CLOSING</p><p>   * ARYA SCIENCES ACQUISITION CORP IV -  TRANSACTION IMPLIES A POST-TRANSACTION FULLY DILUTED ENTERPRISE VALUE OF $113 MILLION OF COMBINED CO</p><p>   * ARYA SCIENCES ACQUISITION CORP IV: INC.\" COMBINED CO'S COMMON STOCK EXPECTED TO BE LISTED ON NASDAQ UNDER TICKER SYMBOL \"ADGM\"</p><p>   * ARYA SCIENCES ACQUISITION CORP IV -  CURRENT INVESTORS IN ADAGIO MEDICAL ARE EXPECTED TO OWN ABOUT 10.2% OF COMBINED CO</p><p>   * ARYA SCIENCES ACQUISITION CORP IV -  PERCEPTIVE AND ARYA SCIENCES HOLDINGS IV COLLECTIVELY, ARE EXPECTED TO HOLD ABOUT 58.2% OF COMBINED CO</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Adagio Medical To List On Nasdaq Through Business Combination With ARYA Sciences Acquisition Corp IV</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Adagio Medical To List On Nasdaq Through Business Combination With ARYA Sciences Acquisition Corp IV\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-02-14 19:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Feb 14 (Reuters) - <a href=\"https://laohu8.com/S/ARYD\">ARYA Sciences Acquisition Corp IV</a></p><p> :</p><p>   * ADAGIO MEDICAL TO LIST ON NASDAQ THROUGH BUSINESS COMBINATION WITH ARYA SCIENCES ACQUISITION CORP IV, ENABLING FURTHER COMMERCIAL AND CLINICAL DEVELOPMENT OF INNOVATIVE CARDIAC ABLATION TECHNOLOGIES</p><p>   * ARYA SCIENCES ACQUISITION CORP IV - TRANSACTION IMPLIES A POST-TRANSACTION FULLY DILUTED EQUITY VALUE OF COMBINED COMPANY OF $128 MILLION</p><p>   * ARYA SCIENCES ACQUISITION CORP IV: COMBINED CO EXPECTS TO RECEIVE ABOUT $42 MILLION FROM EQUITY AND CONVERTIBLE NOTE INVESTORS AT CLOSING</p><p>   * ARYA SCIENCES ACQUISITION CORP IV -  TRANSACTION IMPLIES A POST-TRANSACTION FULLY DILUTED ENTERPRISE VALUE OF $113 MILLION OF COMBINED CO</p><p>   * ARYA SCIENCES ACQUISITION CORP IV: INC.\" COMBINED CO'S COMMON STOCK EXPECTED TO BE LISTED ON NASDAQ UNDER TICKER SYMBOL \"ADGM\"</p><p>   * ARYA SCIENCES ACQUISITION CORP IV -  CURRENT INVESTORS IN ADAGIO MEDICAL ARE EXPECTED TO OWN ABOUT 10.2% OF COMBINED CO</p><p>   * ARYA SCIENCES ACQUISITION CORP IV -  PERCEPTIVE AND ARYA SCIENCES HOLDINGS IV COLLECTIVELY, ARE EXPECTED TO HOLD ABOUT 58.2% OF COMBINED CO</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QQQ","symbol_name":"纳指100ETF","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2411437262","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2411437262","pubTimestamp":1707909602,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Feb 14  - ARYA Sciences Acquisition Corp IV :   * ADAGIO MEDICAL TO LIST ON NASDAQ THROUGH BUSINESS COMBINATION WITH ARYA SCIENCES ACQUISITION CORP IV, ENABLING FURTHER COMMERCIAL AND CLINICAL DEVELOPMENT OF INNOVATIVE CARDIAC ABLATION TECHNOLOGIES   * ARYA SCIENCES ACQUISITION CORP IV - TRANSACTION IMPLIES A POST-TRANSACTION FULLY DILUTED EQUITY VALUE OF COMBINED COMPANY OF $128 MILLION   * ARYA SCIENCES ACQUISITION CORP IV: COMBINED CO EXPECTS TO RECEIVE ABOUT $42 MILLION FROM EQUITY AND CONVERTIBLE NOTE INVESTORS AT CLOSING   * ARYA SCIENCES ACQUISITION CORP IV -  TRANSACTION IMPLIES A POST-TRANSACTION FULLY DILUTED ENTERPRISE VALUE OF $113 MILLION OF COMBINED CO   * ARYA SCIENCES ACQUISITION CORP IV: INC.\" COMBINED CO'S COMMON STOCK EXPECTED TO BE LISTED ON NASDAQ UNDER TICKER SYMBOL \"ADGM\"   * ARYA SCIENCES ACQUISITION CORP IV -  CURRENT INVESTORS IN ADAGIO MEDICAL ARE EXPECTED TO OWN ABOUT 10.2% OF COMBINED CO   * ARYA SCIENCES ACQUISITION CORP IV -  PERCEPTIVE AND ARYA SCIENCES ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"QQQ":"纳指100ETF","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SQQQ":"纳指三倍做空ETF","QID":"两倍做空纳斯达克指数ETF-ProShares","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD",".IXIC":"NASDAQ Composite","BK4112":"金融交易所和数据","PSQ":"做空纳斯达克100指数ETF-ProShares","BK4588":"碎股","BK4539":"次新股","TQQQ":"纳指三倍做多ETF","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4585":"ETF&股票定投概念","QLD":"2倍做多纳斯达克100指数ETF-ProShares","ARYE":"ARYA Sciences Acquisition Corp V","NDAQ":"纳斯达克OMX交易所"},"translate_title":"简介-Adagio Medical将通过与ARYA Sciences Acquisition Corp IV的业务合并在纳斯达克上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SQQQ":0.6,".IXIC":1,"TQQQ":0.6,"NQmain":0.6,"PSQ":0.6,"ARYD":1,"QID":0.6,"QQQ":0.6,"QLD":0.6,"MNQmain":0.6,"NDAQ":1,"ARYE":1},"content_text":"Feb 14 (Reuters) - ARYA Sciences Acquisition Corp IV :   * ADAGIO MEDICAL TO LIST ON NASDAQ THROUGH BUSINESS COMBINATION WITH ARYA SCIENCES ACQUISITION CORP IV, ENABLING FURTHER COMMERCIAL AND CLINICAL DEVELOPMENT OF INNOVATIVE CARDIAC ABLATION TECHNOLOGIES   * ARYA SCIENCES ACQUISITION CORP IV - TRANSACTION IMPLIES A POST-TRANSACTION FULLY DILUTED EQUITY VALUE OF COMBINED COMPANY OF $128 MILLION   * ARYA SCIENCES ACQUISITION CORP IV: COMBINED CO EXPECTS TO RECEIVE ABOUT $42 MILLION FROM EQUITY AND CONVERTIBLE NOTE INVESTORS AT CLOSING   * ARYA SCIENCES ACQUISITION CORP IV -  TRANSACTION IMPLIES A POST-TRANSACTION FULLY DILUTED ENTERPRISE VALUE OF $113 MILLION OF COMBINED CO   * ARYA SCIENCES ACQUISITION CORP IV: INC.\" COMBINED CO'S COMMON STOCK EXPECTED TO BE LISTED ON NASDAQ UNDER TICKER SYMBOL \"ADGM\"   * ARYA SCIENCES ACQUISITION CORP IV -  CURRENT INVESTORS IN ADAGIO MEDICAL ARE EXPECTED TO OWN ABOUT 10.2% OF COMBINED CO   * ARYA SCIENCES ACQUISITION CORP IV -  PERCEPTIVE AND ARYA SCIENCES HOLDINGS IV COLLECTIVELY, ARE EXPECTED TO HOLD ABOUT 58.2% OF COMBINED COSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}